Over the last few years, a detailed map of genetic and epigenetic lesions that underlie multiple myeloma (MM) has been created. Regulation of microRNA (miR)-dependent gene expression and mRNA splicing play significant roles in MM pathogenesis; however, to date an interplay between these processes is not yet delineated. Here we investigated miR-mediated regulation of splicing networks at the transcriptome level. Our studies show that a significant number (78%) of miRs which are either up-or down-regulated in patient CD138+ MM cells, but not in healthy donors (HD) CD138+ plasma cells (PC), target genes involved in early stages of pre-mRNA splicing. We also identified deregulated miRs that target core splicing factors (SF) and modifiers (SM, enhancers/silencers) which cause altered splicing in MM. Our studies suggest that Let-7f, in combination other miRs which are frequently and significantly deregulated in patients with overt MM, targets genes that regulate intron excision. Importantly, deregulated expression of certain miRs in MM promote increased intron retention, a novel characteristic of the MM genome, by inducing deregulated expression of the genes that regulate the splicing network. Our studies, therefore, provide the rationale for therapeutically targeting deregulated miRs to reverse aberrant splicing and improve patient outcome in MM.
Introduction
Recent genomic studies have revealed new molecular characteristics of MM including recurrent mutations, copy number variations, as well as deregulated expression of epigenetic modifiers such as non-coding RNAs (miRs) and mRNA processing [1] [2] [3] [4] [5] [6] . Targeting these alterations, alone and combination, may represent novel therapeutic approaches. miRs are non-coding RNAs which belong to a family of small RNA molecules that block mRNA translation, affect mRNA stability, regulate gene expression at the posttranscriptional level, and are an important component of the epigenetic network [7] . MiRs play a significant role in the regulation of various cellular processes [8, 9] . Importantly, miRs play a significant regulatory role in malignant transformation [8, 10] .
Studies in MM have demonstrated the role of miRNAs in disease pathophysiology. For example, genome-wide miR and mRNA expression studies in newly diagnosed MM demonstrated the role of expressed miRNAs in MM progression [11] . Two independent studies reported miR-15a upregulation in newly diagnosed MM [11, 12] , while a study in relapsed/refractory MM reported downregulation of this oncomir [13] . These studies suggest distinct roles of miR-15a in MM at different stages of disease development, highlighting the need to evaluate the functions of single miRs in the context of their target genes and/or gene pools. Multiple other miR-mRNA regulatory circuits have been reported in MM [14] [15] [16] [17] [18] [19] [20] [21] . Interplay between MYC and the miR-17-92 cluster on chromosome 13 has been documented in MM [22] . Specifically, MYC upregulates miR-17-92 cluster, leading to CDKN1A and MDM2 deregulation in mutated TP53 MM cells. Conversely, regulation of MYC through Let-7b mimic with an LNA-GapmeR has been proposed as a novel therapeutic strategy [23] .
RNA-splicing is another circuit of epigenetic regulation in MM. Even though alternative splicing (AS) is a normal process, mistakes are inevitable. Previous studies of single genes and ongoing genome-wide transcriptome evaluation have detected different patterns of splicing alterations in MM patients [3, [24] [25] [26] [27] [28] [29] . MM cells require XBP1 expression and splicing into active XBP1s to grow and survive, and increased expression of spliced XBP1 is associated with poor survival [24, 30] . MMSET is the result of a common t (4;14) translocation in MM and is associated with poor prognosis [31] ; overexpression of MMSET isoforms is due to complex splicing in t(4;14) MM cases [26, [31] [32] [33] . Another example is HAS1 which produces the extracellular matrix molecule Hyaluronan (HA), a ligand of CD44 and RHAMM. HAS1 is spliced in MM patients, and HAS1Vb splice variant overexpression is correlated with a poor outcome [27] . RHAMM is also spliced in MM, and RHAMM-splice variant/RHAMM-FL ratio both increases with disease burden and predicts for poor survival [34] . Importantly, ongoing whole-transcriptome RNA sequencing analysis of samples from newly diagnosed MM patient samples showed that splice variant expression may predict survival better than gene expression alone [35] . Most recently, NSG MM studies have identified recurrent splicing alterations in >30% patients, with the predominant (32%) recurrent alterations being intron retentions [36] .
miR-dependent gene regulation and mRNA splicing both are epigenetic processes that modulate the protein repertoire at the transcriptional level. Although the independent effects of these processes in MM cells have been shown [37] , the interaction between them has not yet been investigated. Our study is the first attempt to define an association between deregulation of miR expression in MM and its effects on pre-mRNA-splicing. Here, we show that a significant number (78%) of the miRs that are deregulated in MM patients modulate expression of splicing factors (SF) and splicing modifiers (SM, enhancers/silencers) which mediate early stages of AS. Moreover, our results also identified new miRs and core SF interactions in MM, which coordinately regulate splicing at the gene expression level. Our analysis further demonstrates that miR Let-7f modulates SF/ SM (PTBP3, KHSPR, EFTUD2, SUPT6H) transcripts that are regulators of intron retention in MM cells, associated with development of aggressive disease. These studies, therefore, provide the framework for novel therapeutics targeting miRs to modulate splicing and improve patient outcome in MM.
Material and methods

Sample preparation and miR expression profiling
After obtaining written informed consent, we evaluated miR expressions in tumor cells from 78 patients with newly diagnosed MM, as well as from 9 healthy donors (HD) and 12 MM cell lines. Details of these analyses are described in Supplementary Method S1-S2.
In silico target genes prediction and annotation analyses
The web server DIANA-miRPath-V.3 [38] and the Database for Annotation, Visualization, and Integrated Discovery (DAVID) [39] was used to assess merged effects of deregulated miRs in MM on RNA processing. Details of these analyses are described in Supplementary Method S3.
Target gene expression profiling
Target gene expression profiles were evaluated in 41-MM, 33 monoclonal gammopathy of undetermined significance (MGUS), smoldering MM (sMM), and 5-HD. Dataset GDS4968 was downloaded from the GEO. Data were analyzed using the Partek Genomics Suite, according to the standard pipeline.
Cell culture and transient transfection of the antagomir/pre-miR Our studies were carried out on OPM2 MM cell line. We used DMRIE-C and Oligofectamine (2:1) reagent cocktails. These cells were transfected with LNA antagomir anti-Let-7f and/or pre-miR-155 according to the manufacturer's instructions (Exiqon/Ambion). As a control, OPM2 cells were transfected with a scrambled antagomir. Probes were custom conjugated with fluorophores to monitor their proper delivery by flow cytometry or fluorescent microscopy ( Supplementary Fig. 1 ).
Results
miR expression profiling in MM patients
In order to define unique miR signatures in MM, we performed genome-wide mature miR expression profiling of purified CD138
+ MM cells from patients, HD plasma cell (HD-PC) samples, and MM cell lines. We first compared expression profiles of 141 filtered miRs in all MM patients to the miR expression levels detected in HD-PC. This analysis identified one upregulated intronic miR (miR193b) in 40% of MM samples (p = 0.0001); as well as 16 downregulated miRs that were >20 fold downregulated in MM patients relative to HD-PC. The frequency of these downregulated miRs in MM patients ranged from 45 to 85% (Supplementary Table 1A ). An unsupervised, hierarchical clustering analysis of 141 filtered miRs identified two major groups amongst MM patients (Fig. 1, Groups-A and -B) . All MM cell lines were grouped together and formed a subnode with Group A (32 patients), while all HD samples were grouped together with Group-B (34 patients). Based on our unsupervised clustering analyses, Group-A patients have similar proliferation index as cell lines, since they cluster together and share similar miR profiles.
We next performed miRs expression profiling in Group-A and -B patient samples compared to HD-PCs. In Group-A, miR expression profiling identified significant upregulation of intergenic/intronic, intronic/UTR, and intronic miRs; as well as downregulation of exonic, intergenic, UTR, and intronic miRs, compared to HD-PCs (Supplementary Table 1B ). miR expression profile in Group-B identified only one upregulated intergenic miR; as well as exonic, UTR, intergenic, and intronic downregulated miRs, compared to HD-PCs (Supplementary Table 1C ). Importantly, our analysis demonstrates that the intergenic miR Let-7f (70% patients) and intronic miR-585 (80% patients) are most significantly (P = 0.001) and most frequently upregulated in MM patients. In Group-A samples, expression of miR-585 was 9 ± 0.3 fold higher and Let-7f 6.4 ± 0.29 fold higher than in HD-PC; in contrast, in Group-B samples their expression is downregulated compared to HD-PC ( Supplementary Fig. 2 ). The miR expression profiling did not identify differentially expressed miRs in Group C patient samples as compared to miRNA expression in HD PC. Thus, we focus our studies on Group A and Group B patients.
We next compared altered expression levels of miRs between Group-A and Group-B patients. We identified 5 miRs, which were significantly downregulated in both Groups-A and -B (Supplementary Table 1B, C) . Furthermore, We identified miRs that were significantly downregulated only in Group-A or Group-B patients (Supplementary Table 1B, C). No common miR was upregulated between the two groups. This significant downregulation of miRs, which is due to defective miR biogenesis, is a general characteristic of many types of malignancies including myeloma.
Identification of pathways regulated by differentially expressed miRs in MM patients
We next used the miR pathway analysis web-server DIANA-miRPath to identify pathways targeted by those miRs which are deregulated (up-or downregulated) in MM patient samples. These analyses showed that 78% (18 of 23) miRs deregulated in MM patients target genes involved in RNA processing, specifically RNA splicing (Supplementary Tables 2-3) . Consistent results were obtained from analyses of miRs deregulated in Group-A and Group-B patients: 69% (11 of 16) and 93% (13 of 14) deregulated miRs were evident in Groups-A and -B, respectively, targeting genes involved in mRNA processing (Supplementary Table 3) . The above analyses showed that a significant number of the genes targeted by upregulated miRs in MM patient samples vs HD-PC mapped to chromosomes (Ch)-1, -2, -17, -19 vs Ch-1, respectively (Fig. 2a) . In contrast, downregulated miRs in Groups-A vs Group-B MM patients target genes mapped to Ch-1, -6, and -17, vs Ch-1 and -17, respectively.
Next, we determined the biological features of genes targeted by miRs deregulated in MM patients. We performed GO annotation and KEGG enrichment analyses of target genes by querying DAVID-v6.8. database. GO CC annotation showed that a significant number of gene products targeted by deregulated miRs are enriched in the nucleus (>60%) and nucleoplasm (>75%), and are part of spliceosome complexes (~48%) (Fig. 2b, Supplementary  Table 3A) . To examine the function of miRs differentially expressed in MM, we next annotated miR target genes based on their molecular functions and determined their associations with biological processes. According to BP annotation, genes targeted by miRs upregulated in MM are enriched for gene products which are components of the spliceosome complex involved in mRNA 3'end processing, RNA capping, export from the nucleus, regulation of nuclear import, as well as transesterification reactions or regulation of transcription (Fig. 2c , Supplementary  Table 3B) .
Finally, we carried out deregulated miR target gene enrichment analyses, and identified a number of signaling pathways affected by deregulated miRs (P < 0.005). We specifically identified four signaling pathways affected by upregulated miRs, and four pathways affected by downregulated miRs. Our studies suggest that pathways commonly modulated by deregulated miRs control spliceosome assembly, mRNA stability, and mRNA transport (Table 1) . Furthermore, multiple genes within each pathway are targeted by deregulated miRs, suggesting coordinated control of affected pathways by deregulated miRs (Fig. 3a, b) .
Validation of deregulated miR target genes in MM patients
We next validated the expression of those transcripts targeted by deregulated miRs in Dataset GDS4968. We performed unsupervised clustering analyses of deregulated miR target genes, and identified their expression levels compared to HD-PC. Our analyses showed that one cluster is enriched with MM samples and the other with sMM samples regardless of whether miRs are upregulated or downregulated. These clusters are not homogeneous, since our clustering analyses were done on a small number of genes selectively targeted by deregulated miRs (Fig. 4) .
We evaluated expression profiles of transcripts targeted by Group-A and Group-B up-and down-regulated miRs as compared to HD-PC. Among the 85 genes targeted by Group-A upregulated miRs, we identified 36 transcripts that are differentially expressed (22-downregulated, 14-upregulated) in MM patients compared to HD-PC (P < 0.05, Fig. 4a ). In Group-B, we found only 4 genes significantly altered by upregulated miRs. Analysis of genes targeted by downregulated miRs showed that 28 of 80 genes were significantly deregulated (11-upregulated, 17-downregulated) by Group-A miRs, while 35 of 91 genes were significantly differentially expressed (15-upregulated, 20-downregulated) by Group-B miRs (Fig. 4b) . Gene enrichment and annotation analyses showed that most of the downregulated target genes are involved in the formation of exon junction complexes or regulate pre-mRNA 3'-end processing; or are affecting U1, U2, U4/6, and U5 spliceosome components. Some genes are part of Complex-A or a post-spliceosomal complex, while others are involved in the assembly of Complex-B during the splicing process (Fig. 3b) .
Effects of Let-7f on splicing molecules in MM
To evaluate the functional consequences of deregulated miRs in MM patients, we focused our validation studies on Let-7f, since it is most frequently and significantly deregulated in MM patient samples. Using DIANA-miRPath, we first identified 46 genes targeted by Let-7f (Table 2) , and then performed GO annotation and gene enrichment analyses of target genes. This analysis showed that a significant number of Let-7f target gene products are localized in the nucleoplasm and nucleus, and are part of intracellular RNP complexes (Fig. 5a ). We next annotated Let-7f target genes based on their biological function, which included regulation of splicing processes, mRNA transcription, and mRNA 3'end processing (Fig. 5a ). Furthermore, target gene enrichment analyses identified 4 signaling pathways affected by Let-7f, most prominently mRNA processing pathways (Fig. 5b) .
We then evaluated impact of Let-7f on expression of 47 targeted genes in 20 patients with MGUS, 33 patients with high-risk sMM, 41 patients with MM, and 5 HD PCs. Unsupervised clustering analyses showed that 83% (34 of 41) MM samples clustered together and formed a subnode with 85% (30 of 33) MGUS samples, while 83% (28 of 33) sMM samples clustered with HD PC samples (Fig. 5b) . Among the 47 deregulated genes, 17 are significantly downregulated and 9 are significantly upregulated (P < 0.05) in MM patients. B) Spliceosome Components A) RNA processing pathway Fig. 3 Example diagram adapted from the DAVID database that shows the mRNA splicing process, spliceosome components, and splicing complexes. Putative target genes of deregulated miRs involved in the splicing pathway are marked with a red star These analyses showed that 68% genes are downregulated in MM and MGUS patients and share the same gene expression profiles, which are distinct from those detected in sMM patients. The downregulated gene list includes splicing factors which regulate spliceosome biogenesis, as well as splicing molecules which are involved in mRNA polyadenylation and mRNA surveillance pathways (Fig. 5a) .
To validate whether Let-7f regulates predicted target genes, we used LNA antagomir Let-7f to downregulate this miR in OPM2 cells, which express high levels of Let-7f.
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Genome-wide expression profiling (Fig. 5b ) in transfected cells showed that Let-7f target genes that were significantly downregulated in MM, MGUS, and sMM patients were upregulated after Let-7f inhibition, suggesting direct regulation of these genes by Let-7f (Fig. 5c marked) . Annotation analyses showed that downregulated gene products are localized in the nucleus, nucleoplasm, chromosome, cytoplasm, and cytosol. They are involved in RNA splicing via transesterification reaction, mRNA processing, RNA metabolic processes, negative regulation of RNA splicing, and transcription, as well as in other processes described in Supplementary Table 4 . Of note, the downregulated genes include a core splicing factor PTBP3, which binds to a polypyrimidine tract of splicing (PPT) a component of the PPT binding complex (KHSPR); and EFTUD2, a component of U5-snRNP. Importantly, these proteins regulate intron excision during splicing [40] [41] [42] . Alteration of this process results in intron retention, a novel epigenetic characteristic of the MM genome. Our studies, therefore, suggest that intron retention in MM patients can be modulated via targeting Let-7f and other deregulated miRNAs in MM.
We then went on to validate the role of Let-7f in vitro and in vivo on MM tumor burden. We tested Let-7f alone and in combination with miR-155, because modulation of these miRs was observed most frequently in the Group A patient cohort, which includes patients with high and intermediated cytogenetic-risk profile. Based on DIANAmiRPath, we identified 19 genes targeted by miR-155 including: DDX39B, which is an essential splicing factor required for association of the U2 protein complex with premRNA; SRSF2 protein, which is required for formation of the earliest splicing complex and is involved in bridging the 5-and 3-splice sites and in U1 and U2 spliceosome assembly; and heterogeneous nuclear ribonucleoprotein A3, that plays a role in cytoplasmic trafficking of RNA. We found these target genes to be downregulated in MM patients, which suggests translational repression of target genes by miR-155.
We next evaluated the role of Let-7f and miR-155 in MM cell line OPM2 by gain-and loss-of function experiments. We used LNA anti-miR probes for loss of function and pre-miR-155 for gain of function studies, alone or in combination. Although manipulation of these miRs induced 20-25% change in OPM2 cell proliferation and/or induction of apoptosis, the combination of antagomir Let-7f with pre-miR-155 significantly decreased MM cell proliferation and induced apoptosis (Fig. 6a, b) .
We went on to evaluate efficacy of these miRs in an in vivo murine xenograft model of human MM to determine their therapeutic potential. Human MM-bearing mice were treated intraperitoneally for four consecutive days with the LNA antgomir Let-7f and pre-miR-155 probes, alone and in combination, and with scramble miR. We observed that the single LNA anti-Let-7f and premiR-155 treatment reduced tumor size by 36% after 7 days treatment (Fig. 6c) . More significant tumor size reductions were achieved when animals were treated with combinations; for example, 58% reduction in tumor after antagomir Let-7f plus pre-miR-155 treatment. We did not observe any significant systemic toxicity in the animals. Our results, therefore, suggest identify a biological role for Let-7f and miR-155 both in MM in both in vitro and in vivo models, and suggest potential of novel therapeutics targeting these miRs.
Discussion
Multiple transcriptome modifiers play a critical role in determining growth and survival of cancer cells, including MM cells [5, 6] . These modifiers include small non-coding RNAs such as miRs, and a large repertoire of molecules involved in pre-mRNA/mRNA processing [9, 11, 43, 44] .
Pathway name # of genes involved % of genes involved P-Value
In this study, we delineate the interplay between these two processes in MM cells. We evaluated miR expression profiles in MM patient and HD-PC samples, since miRs are modulators of gene expression that influence malignant cell growth by controlling protein expression. The majority of miRs identified in our studies were downregulated in MM compared to HD-PCs, consistent with prior reports in MM as well other hematologic malignancies and solid tumors [11, 45] . We next investigated target genes and identified pathway signatures affected by miRs that were significantly (P < 0.05) deregulated in MM samples. We focused on pathways that control pre-mRNA processing, since these pathways together with miRs control global gene expression. To delineate interactions between miR expression and mRNA processing, specifically splicing, we evaluated whether deregulated miRs in MM patients target SF or SM (splicing enhances and/or silencers). Importantly, gene and pathway enrichment analyses suggested that 78% deregulated miRs target genes involved in pre-mRNA splicing (Fig. 2) . Moreover, most deregulated miR target genes mapped to Ch-1, -6, and -17. Of note, some deregulated miRs in MM are encoded by genes originating from introns. For example, in MM patients we identified 13 (60%) intronic miRs among 22 deregulated miRs. These intronic miRs, unlike intragenic or intergenic miRs, are processed from the introns of their host gene and share common regulatory mechanisms, and consequently expression patterns. These analyses, therefore, demonstrated that deregulated miRs in MM patients control the expression of genes on Ch1q and Ch17p, both of which contribute to disease pathogenesis and may confer poor prognosis.
Our analyses also showed that genes targeted by the upregulated miRs in MM are enriched for genes encoding proteins in the spliceosome complex; involved in transesterification reactions, mRNA capping, and polyadenylation; and regulating mRNA export from the nucleus (Fig. 2c) . Furthermore, deregulated miR target gene enrichment analyses identified those pathways that control U2 and U6 spliceosome complex assembly, mRNA stability and transport. Our validation studies in MM, MGUS, sMM and HD-PC transcriptomes identified a distinct miR target gene expression pattern in MM patient samples that is a reflection of the actual miR expression patterns (Fig. 4) . These findings, therefore, suggest that the effects of deregulated miRs may play role in regulating the mRNA processing network, specifically splicing, and that these alterations contribute to the aberrant splicing mechanisms identified in MM patients.
Pre-mRNA-splicing is a complex process catalyzed cotranscriptionally by the spliceosome; it is accomplished via two transesterification reactions. Spliceosome assembly and the formation of complexes E, A, and B complexes characterizes the first transesterification reaction, while C complex promotes catalysis of this reaction [46] . The E, A, and B complexes are formed as a result of an extensive rearrangement of U1, U2, U4, U5, and U6 small nuclear ribonucleoproteins (snRNP) that must recognize the exon-intron boundaries [46] [47] [48] . The 3' end of any given intron consists of two conserved sequence elements, a splicing branch point (BP) and a polypyrimidine tract (PPT) of splicing. These classical splicing elements are sites were snRNPs are assembled as a spliceosome complex. At the end of the first transesterification reaction, the 2'-hydroxyl group of the branch point adenosine residue "attacks" the phosphate group of the 5' splice site, leading to cleavage of the 5' splice site from the adjacent exon; then the 5' splice site is ligated to the BP [46, 47] . The first transesterification reaction results in a detached 5' exon and the 3'exon/intron in a lariat structure and can be influenced by the differential expression of snRNPs. Here, we found that upregulated miRs target U1 and U2 snRNPs and cause their downregulation (Fig. 4) . In the same group of patients, we found downregulated miRs targeting U6 snRNP. Thus, our studies further suggest that formation of E, A, and B splicing complexes are altered in MM patients, which could lead to aberrant splicing including partial exon skipping and/or intron retention characteristic of MM cells. Furthermore, normal intron processing, a detachment of the intron from the 3'end of exon, can be influenced by splicing enhancer or suppressor snRNPs that bind to introns during assembly of spliceosome complexes. It is well established that intronic splicing can be caused by splicing enhancer and suppressor snRNPs that bind to BP and PPT of splicing elements on given pre-mRNA transcripts [49] . In our validation studies, we found that Let-7f, which is frequently deregulated in MM patients, targets genes that are involved in intron processing; and that their downregulation leads to alterations in this process. The downregulated genes include: a core splicing factor PTBP3, which binds to a polypyrimidine tract of splicing (PPT); and KHSPR, which is part of the PPT binding complex that binds specifically to an intronic splicing enhancer; both proteins are involved in intron processing [41, 50, 51] . In addition, it is reported that KHSPR regulates miR biogenesis [52] . Thus, miR splicing factor regulation can be bidirectional in MM. Here we focused on effects of miRs on RNA processing, and the effects of splicing on miR biogenesis in MM are the object of ongoing studies.
Two other downregulated target genes are: [1] EFTUD2, a component of U5 snRNP which is involved in bridging the 5'-and 3'-splice sites and is required in U1 and U2 assembly, the first catalytic reaction of splicing; and [2] SUPT6H, which is involved in chromatin organization remodeling, specifically H3-K27 methylation [46, 52] . It has been shown that 3 was reached in the cohort (4 mice/group). Then, an appropriate group of mice was treated with the anti-Let-7f antagomir, pre-miR-155, or anti-Let-7f + pre-miR-155; a control group of mice was treated with scrambled probes (SC). All animals were treated via tail vein injection and treatments were administered on days 1-4, and days 8-11 after animals were randomized. Tumor volume was evaluated by caliper measurement. Differences between the groups were evaluated by standard t-tests (GraphPad Software). Animal handling methods are consistent with the recommendations of the Panel on Euthanasia of the American Veterinary Medical Association chromatin structure perturbation via histone depletion results in drastic alterations in the splicing process [53] . Regulation of these splicing factor/molecules by Let-7f in MM is selective, evidenced by knockdown experiments which demonstrate that expression of all four genes (PTBP3, KHSPR, EFTUD2, and SUPT6H) is significantly (P < 0.005) restored after transfections of OPM2 cells with the anti-Let-7f antagomir. Our studies, therefore, suggest that deregulated miRs in MM modulate expression of genes that encode proteins mediating early splicing mechanisms. Furthermore, our findings indicate that increased intron retention, a novel characteristic of the MM genome, can be regulated and corrected by modulating miR expression using LNA antagomirs and/or pre-miRs to modify core splicing factors and/or the splicing network in MM.
Finally, our gain-and loss-of function ex vivo and in vivo experiments show combined effects of deregulated miRs in MM on tumor burden. These studies showed that both antiLet-7f and pre-miR-155, alone and to a greater extent when combined, inhibited in vivo tumor growth (Fig. 6 ). Our studies, therefore, provide the framework for targeting deregulated miRs with novel therapeutics to reverse altered splicing and improve patient outcome in MM.
